NCT03645057View on ClinicalTrials.gov

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

Crisaborole

This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.

DRUG

Tacrolimus 0.03% Ointment

This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.

Trial Locations (1)

14642

University of Rochester Dermatology, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT03645057 - ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis | Biotech Hunter | Biotech Hunter